Top

Published in:

2022 | OriginalPaper | Chapter

The Role of Cell-Free RNA in Clinical Diagnosis and Evaluation of Cell-Free RNA Extraction Methods

Authors : Anh Phuc Hoang Le, Ha Thi Thanh Huong

Published in: 8th International Conference on the Development of Biomedical Engineering in Vietnam

Publisher: Springer International Publishing

Activate our intelligent search to find suitable subject content or patents.

search-config

AI-assisted search

Off

Abstract

Cell-free RNA (cf-RNA) is released from cells and circulated in the body via the circulatory and endocrine systems. Subsequently, cf-RNA can be extracted from different biofluids by various extraction methods. This review aims to: (1) clarify the clinical role of cf-RNA and methods of extraction, (2) introduce the evaluation parameters and methods, (3) summarize the evaluation of several common extraction methods and propose optimizing solutions for them. Eighty articles on the application of cf-RNA in diagnosing diseases and cf-RNA extraction published in journals with good impact factor (higher than 2) were then summarized and sorted into groups based on their targeted disease: (1) Cancers and (2) Neurodegenerative diseases since the cf-RNA is being studied mainly in these two fields. The general design of these studies is comparing cf-RNA to the current means of diagnosis, which are considered as standards such as endoscopy, biopsy, CSF analysis. By quantifying cf-RNA using qRT-PCR, previous studies were able to detect several cancers and neurodegenerative diseases. The key advantage of using the cf-RNA as a biomarker is reducing the risks and invasiveness without losing sensitivity since it can be extracted in the peripheral area. Furthermore, cf-RNA expression levels vary according to disease stages, suggesting its potential as prognostic markers. The main challenge in using cf-RNA is achieving the optimal yield, purity, integrity with minimal contamination. The current methods like Trizol LS, miR-Neasy, mirVANA have yielded unsatisfying results; therefore, they require modifications to optimize their results. miRCURY kit has the highest RNA yield but has been discontinued. In conclusion, cf-RNA holds excellent promises as a promising biomarker in the future. However, due to certain challenges, the use of cf-RNA is currently limited to clinical studies due to the instability in yield and integrity, requiring supporting studies and extraction methods evaluation.

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

inform now

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

inform now

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 340 Zeitschriften

aus folgenden Fachgebieten:

Bauwesen + Immobilien
Business IT + Informatik
Finance + Banking
Management + Führung
Marketing + Vertrieb
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

inform now

previous chapter Identification of Bacterial Profile in Root Canals of Teeth with Chronic Periapical Lesions in Vietnam

next chapter Study on Extracting Crude Phycocyanin from Spirulina Algae and Determining Its Ability in Protecting Fibroblasts from Oxidative Stress of Hydroxyl Peroxide

Cerebrospinal fluid.

Institutional Review Board—Ethics and Informed Consent.

Huynh RA, Mohan C (2017) Alzheimer’s disease: biomarkers in the genome, blood, and cerebrospinal fluid. Front Neurol 8:102CrossRef

Naylor S (2003) Biomarkers: current perspectives and future prospects. Expert Rev Mol Diagn 3(5):525–529CrossRef

Mayeux R (2004) Biomarkers: potential uses and limitations. NeuroRx 1(2):182–188CrossRef

Etheridge AaL, Inyoul, Hood L, Galas D, Wang K (2011) Extracellular microRNA: a new source of biomarkers. Mut Res 717:85–90

Galasko D (2001) New approaches to diagnose and treat Alzheimer’s disease: a glimpse of the future. Clin Geriatr Med 17(2):393–410CrossRef

Reiber H, Peter JB (2001) Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J Neurol Sci 184(2):101–122CrossRef

Rohlff C (2001) Proteomics in neuropsychiatric disorders. Int J Neuropsychopharmacol 4(1):93–102CrossRef

Verbeek MM, De Jong D, Kremer HP (2003) Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases. Ann Clin Biochem 40(Pt 1):25–40CrossRef

Kubiritova Z, Radvanszky J,Gardlik R (2019) Cell-free nucleic acids and their emerging role in the pathogenesis and clinical management of inflammatory bowel disease. Int J Mol Sci 20(15)

10.

Yuan T et al (2016) Plasma extracellular RNA profiles in healthy and cancer patients. Sci Rep 6:19413CrossRef

11.

Lässer C (2012) Exosomal RNA as biomarkers and the therapeutic potential of exosome vectors. Exp Opin Biol Ther 12(Suppl 1):S189–S197CrossRef

12.

Sadik N et al (2018) Extracellular RNAs: a new awareness of old perspectives. Methods Mol Biol 1740:1–15CrossRef

13.

Schwarzenbach H et al (2011) Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease. Mol Biosyst 7(10):2848–2854CrossRef

14.

Xi X et al (2017) RNA biomarkers: frontier of precision medicine for cancer. Noncoding RNA 3(1)

15.

Rabinowits G et al (2009) Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 10(1):42–46CrossRef

16.

Papadopoulou E et al (2006) Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer. Ann N Y Acad Sci 1075:235–243CrossRef

17.

Cheng Y et al (2010) A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin Sci (Lond) 119(2):87–95CrossRef

18.

Wang G et al (2010) Serum and urinary cell-free MiR-146a and MiR-155 in patients with systemic lupus erythematosus. J Rheumatol 37(12):2516–2522CrossRef

19.

Jessica A, Dietz KLJ, Lauren JM, Schaper J, Horlitz M, Cowan J, Bianchi DW (2011) Comparison of extraction techniques for amniotic fluid supernatant demonstrates improved yield of cell-free fetal RNA. Prenatal Diagnosis

20.

Kiko T et al (2014) MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer’s disease. J Alzheimers Dis 39(2):253–259CrossRef

21.

Fleige S et al (2006) Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR. Biotechnol Lett 28(19):1601–1613CrossRef

22.

Spornraft M et al (2014) Optimization of extraction of circulating RNAs from plasma—enabling small RNA sequencing. PLoS One 9(9):e107259

23.

Becker C et al (2010) mRNA and microRNA quality control for RT-qPCR analysis. Methods 50(4):237–243CrossRef

24.

Kirschner MB et al (2013) The impact of hemolysis on cell-free microRNA biomarkers. Front Genet 4:94

25.

Pritchard CC et al (2012) Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila) 5(3):492–497CrossRef

26.

Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) (2019) Cochrane handbook for systematic reviews of interventions. J.W. Sons

27.

McGuinness LAR (2019) An R package and web application for visualising risk-of-bias assessments. 2019 [cited 2020 May 13]. Available from: https://github.com/mcguinlu/robvis

28.

Kopreski MS, Christopher D. Gocke (2005) Method of detecting tumor-associated DNA in plasma or serum with a premalignant solid tumor (U.S. Patent No. US 8,361,726 B2), U.S. Patent and Trademark Office, Washington, DC.

29.

Joosse SA et al (2014) Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases. Br J Cancer 111(5):909–917CrossRef

30.

Eichelser C et al (2013) Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin Chem 59(10):1489–1496CrossRef

31.

Kim WT et al (2016) UBE2C cell-free RNA in urine can discriminate between bladder cancer and hematuria. Oncotarget 7(36):58193–58202CrossRef

32.

Munagala R, Aqil F, Gupta RC (2016) Exosomal miRNAs as biomarkers of recurrent lung cancer. Tumour Biol 37(8):10703–10714CrossRef

33.

Schwarzenbach H (2013) Circulating nucleic acids as biomarkers in breast cancer. Breast Cancer Res 15(5):211CrossRef

34.

Silva JM et al (2002) Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Gut 50(4):530–534CrossRef

35.

Maciotta S, Meregalli M, Torrente Y (2013) The involvement of microRNAs in neurodegenerative diseases. Front Cell Neurosci 7:265CrossRef

36.

Cardo LF et al (2013) Profile of microRNAs in the plasma of Parkinson’s disease patients and healthy controls. J Neurol 260(5):1420–1422CrossRef

37.

Cogswell JP et al (2008) Identification of miRNA changes in Alzheimer’s disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis 14(1):27–41CrossRef

38.

Tielking K et al (2019) Extracellular RNA in central nervous system pathologies. Front Mol Neurosci 12:254CrossRef

39.

Waller R et al (2017) Small RNA sequencing of sporadic amyotrophic lateral sclerosis cerebrospinal fluid reveals differentially expressed miRNAs Related to neural and glial activity. Front Neurosci 11:731CrossRef

40.

Burgos K et al (2014) Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease status and features of pathology. PLoS One 9(5):e94839

41.

Nussbaum RL, Ellis CE (2003) Alzheimer’s disease and Parkinson’s disease. N Engl J Med 348(14):1356–1364CrossRef

42.

Shaw LM et al (2009) Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol 65(4):403–413CrossRef

43.

Welge V et al (2009) Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer’s disease. J Neural Transm (Vienna) 116(2):203–212CrossRef

44.

Bhatnagar S et al (2014) Increased microRNA-34c abundance in Alzheimer’s disease circulating blood plasma. Front Mol Neurosci 7:2CrossRef

45.

KOH LCW, Stephen R. Quake, Hei-Mun Christina Fan,Wenying Pan (2013) Methods for profiling and quantitating cell-free rna (World Patent Application No. WO2015069900A1), WIPO (PCT).

46.

Yan Z et al (2020) Presymptomatic increase of an extracellular RNA in blood plasma associates with the development of alzheimer’s disease. Curr Biol 30(10):1771-1782.e3CrossRef

47.

Poewe W et al (2017) Parkinson disease. Nat Rev Dis Primers 3:17013

48.

Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427–442CrossRef

49.

Pollanen MS, Dickson DW, Bergeron C (1993) Pathology and biology of the Lewy body. J Neuropathol Exp Neurol 52(3):183–191CrossRef

50.

Miñones-Moyano E et al (2011) MicroRNA profiling of Parkinson’s disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum Mol Genet 20(15):3067–3078CrossRef

51.

Junn E, Mouradian MM (2012) MicroRNAs in neurodegenerative diseases and their therapeutic potential. Pharmacol Ther 133(2):142–150CrossRef

52.

Agrawal M, Biswas A (2015) Molecular diagnostics of neurodegenerative disorders. Front Mol Biosci 2(54)

53.

Yang YX, Wood NW, Latchman DS (2009) Molecular basis of Parkinson’s disease. NeuroReport 20(2):150–156CrossRef

54.

Ferrara D et al (2018) Role of extracellular vesicles in amyotrophic lateral sclerosis. Front Neurosci 12:574CrossRef

55.

Enderle D et al (2015) Characterization of RNA from exosomes and other extracellular vesicles isolated by a novel spin column-based method. PLoS One 10(8):e0136133

56.

Eldh M et al (2012) Importance of RNA isolation methods for analysis of exosomal RNA: evaluation of different methods. Mol Immunol 50(4):278–286CrossRef

57.

Dotti IaB (2011) Serena, integrity assessment of nucleic acids, pp 81–85

58.

Cerkovnik PaP, Andraz, Zgajnar J, Novakovic S (2007) Optimization of an RNA isolation procedure from plasma samples. Int J Mol Med 20:293–300

59.

Lightfoot S, Salowsky R, Buhlmann C (2005) RNA integrity number: towards standardization of RNA quality assessment for better reproducibility and reliability of gene expression experiments. Breast Cancer Res 7(Suppl 2):P7 05

60.

Wong BC, Lo YM (2006) Plasma RNA integrity analysis: methodology and validation. Ann N Y Acad Sci 1075:174–178CrossRef

61.

Wong BC et al (2006) Reduced plasma RNA integrity in nasopharyngeal carcinoma patients. Clin Cancer Res 12(8):2512–2516CrossRef

62.

Manchester KL (1996) Use of UV methods for measurement of protein and nucleic acid concentrations. Biotechniques 20(6):968–970CrossRef

63.

Hashemipetroudi SH et al (2018) Assessment of DNA contamination in RNA samples based on ribosomal DNA. J Vis Exp (131)

64.

Heireman L et al (2017) Causes, consequences and management of sample hemolysis in the clinical laboratory. Clin Biochem 50(18):1317–1322CrossRef

65.

Müller M et al (2014) MicroRNAs in Alzheimer’s disease: differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiol Aging 35(1):152–158CrossRef

66.

Blondal T et al (2013) Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods 59(1):S1-6CrossRef

67.

Shah JS, Soon PS, Marsh DJ (2016) Comparison of methodologies to detect low levels of hemolysis in serum for accurate assessment of serum microRNAs. PLoS One 11(4):e0153200

68.

Killilea DW et al (2017) Identification of a hemolysis threshold that increases plasma and serum zinc concentration. J Nutr 147(6):1218–1225CrossRef

69.

Li Q et al (2015) Plasma long noncoding RNA protected by exosomes as a potential stable biomarker for gastric cancer. Tumour Biol 36(3):2007–2012CrossRef

70.

Patel T (2018) MARTON, extracellular RNA. Springer Nature, ed. L. Springer Science+ Business Media

71.

Hengen PN (1996) Carriers for precipitating nucleic acids. Trends Biochem Sci 21(6):224–225

72.

Moret I et al (2013) Assessing an improved protocol for plasma microRNA extraction. PLoS One 8(12):e82753

73.

Fernando MR, Luna KK, Lechner JM, Qin J (2012) Stabilization of cell-free RNA in blood samples using a new collection device. Clin Biochem 45(16–17):1497–1502

74.

McAlexander MA, Phillips MJ, Witwer KW (2013) Comparison of methods for miRNA extraction from plasma and quantitative recovery of RNA from cerebrospinal fluid. Front Genet 4:83CrossRef

75.

Zaporozhchenko IA et al (2018) The potential of circulating cell-free RNA as a cancer biomarker: challenges and opportunities. Exp Rev Mol Diagn 18(2):133–145CrossRef

76.

Zhao An, Péoc'h M, Cottier M, Genin C, Mottet N, Li G (2015) Cell-free RNA content in urine as a possible molecular diagnostic tool for clear cell renal cell carcinoma. International Journal of Cancer 136 (11):2610–2615

77.

Srinivasan S, Yeri A, Cheah PS, Chung A, Danielson K, De Hoff P, Filant J, Laurent CD, Laurent LD, Magee R, Moeller C, Murthy VL, Nejad P, Paul A, Rigoutsos I, Rodosthenous R, Shah RV, Simonson B, To, C, ... Laurent LC (2019) Small RNA Sequencing across Diverse Biofluids Identifies Optimal Methods for exRNA Isolation. Cell, 177(2), 446–462.e16.

78.

Kuang J, Yan X, Genders A J, Granata C, & Bishop D J (2018) An overview of technical considerations when using quantitative real-time PCR analysis of gene ex-pression in human exercise research. PloS One, 13(5), e0196438.

79.

Juzenas S, Venkatesh G, Hübenthal M, Hoeppner MP, Du, Z G, Paulsen M, Rosenstiel P, Senger P, Hofmann-Apitius M, Keller A., Kupcinskas L, Franke A., Hemmrich-Stanisak G (2017) A comprehensive, cell specific microRNA catalogue of human peripheral blood. Nucleic Acids Research, 45(16), 9290–9301.

80.

Prendergast E N, de Souza Fonseca M A., Dezem F S, Lester J, Karlan B Y, Noushmehr H, Lin X, Lawrenson K (2018) Optimizing exosomal RNA isola-tion for RNA-Seq analyses of archival sera specimens. PloS One, 13(5), e0196913.

Title: The Role of Cell-Free RNA in Clinical Diagnosis and Evaluation of Cell-Free RNA Extraction Methods
Authors: Anh Phuc Hoang Le
Ha Thi Thanh Huong
Publisher: Springer International Publishing
Book: 8th International Conference on the Development of Biomedical Engineering in Vietnam
Print ISBN: 978-3-030-75505-8

Electronic ISBN: 978-3-030-75506-5

Copyright Year: 2022
DOI: https://doi.org/10.1007/978-3-030-75506-5_53

Springer Professional

Abstract

Please log in to get access to your license.

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Springer Professional "Technik"

Springer Professional "Wirtschaft"

Premium Partner